AlphaValue/Baader Europe Upgrades Novonesis to Add After Q2 Beat

07:19 AM EDT, 08/27/2026 (MT Newswires) -- AlphaValue/Baader Europe upgraded its rating on Novonesis (NSIS-B.CO), noting that the biosolutions company's risk/reward remains "compelling" after it lifted its 2026 outlook following stronger-than-expected second-quarter results. The research firm changed its opinion to add from reduce on Wednesday, with a price target of 511 Danish kroner. "The Q2 26 results marked a clear inflection point: broad-based organic growth (+9%, well ahead of consensus) across both divisions, FY26 guidance raised on genuine demand strength rather than one-off effects, and an inaugural EUR1bn share buyback (H2 26-end-2029), signalling confidence in cash generation and the balance sheet," analysts wrote. "We have improved our medium- to long-term assumptions, and move to ADD."